Iovance Biotherapeutics (IOVA) vs Kodiak Sciences (KOD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kodiak Sciences (KOD) has outperformed Iovance Biotherapeutics (IOVA) over the past year, gaining 551.9% versus a gain of 486.3%. Over five years, KOD leads with a -15.8% price change compared with -50.0% for IOVA. Iovance Biotherapeutics is the larger company by market cap ($6.03 billion vs $5.92 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IOVA | KOD |
|---|---|---|
| Share price | $13.31 | $94.26 |
| Market cap | $6.03B | $5.92B |
| 1-day change | +3.06% | +3.49% |
| YTD return | +387.55% | +237.12% |
| 1-year return | +486.34% | +551.87% |
| 5-year return | -49.98% | -15.82% |
| EPS (TTM) | $-0.69 | $-4.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $263.50M | — |
| Revenue growth (YoY) | +60.60% | — |
| Net income (latest FY) | $-390.98M | $-229.97M |
| Gross margin | 34.28% | — |
| Operating margin | -153.08% | — |
| Net margin | -148.38% | — |
| 52-week high | $15.30 | $104.00 |
| 52-week low | $1.76 | $10.94 |
| Distance from 52-week high | -13.01% | -9.37% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -3.83% | +23.77% |
| Average volume | 17.82M | 1.57M |
| Shares outstanding | 452.97M | 62.85M |
| Employees | 975 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KOD has outperformed IOVA by 65.5 percentage points over the past year.
About Iovance Biotherapeutics
IOVA stock →Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 975 employees
About Kodiak Sciences
KOD stock →Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
IOVA vs KOD FAQ
Which is bigger, Iovance Biotherapeutics or Kodiak Sciences?
Iovance Biotherapeutics (IOVA) is larger, with a market capitalization of $6.03B compared with $5.92B for Kodiak Sciences (KOD).
Which stock has performed better over the past year, IOVA or KOD?
KOD returned +551.87% over the past 12 months, compared with +486.34% for IOVA (price return, excluding dividends). Past performance does not predict future results.
Are Iovance Biotherapeutics and Kodiak Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.